Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with Royalty ...

Cytokinetics has suggested aficamten has a competitive clinical profile to BMS' drug – pointing to strong data on exercise capacity, symptoms, biomarkers, cardiac structure and function ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals for the treatment of patients with obstructive and ...

CEO Robert Blum is “very clear” that the company, which is on track for U.S. approval in September for aficamten to treat a ...

Royalty Pharma said its decision follows feedback from investors that the current structure made it difficult to ... capital for 14 experimental treatments, including Cytokinetics' heart disease drug ...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize ...

Cytokinetics Q3 Loss Wider Than Expected ... III SEQUOIA-HCM study in obstructive HCM showed that treatment with aficamten in SEQUOIA-HCM was associated with improvements in cardiac structure and ...

Royalty Pharma said its decision follows feedback from investors that the current structure made ... including Cytokinetics' heart disease drug aficamten and Novartis' blood cancer drug pelabresib.